Promoter variation in the catechol-O-methyltransferase gene is associated with remission of symptoms during fluvoxamine treatment for major depression

Naoki Fukui; Yutaro Suzuki; Takuro Sugai; Junzo Watanabe; Shin Ono; Nobuto Tsuneyama; Toshiyuki Someya

doi:10.1016/j.psychres.2014.04.030

Promoter variation in the catechol-O-methyltransferase gene is associated with remission of symptoms during fluvoxamine treatment for major depression

Psychiatry Res. 2014 Aug 30;218(3):353-5. doi: 10.1016/j.psychres.2014.04.030. Epub 2014 Apr 28.

Authors

Naoki Fukui¹, Yutaro Suzuki¹, Takuro Sugai¹, Junzo Watanabe¹, Shin Ono¹, Nobuto Tsuneyama¹, Toshiyuki Someya²

Affiliations

¹ Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
² Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Electronic address: psy@med.niigata-u.ac.jp.

PMID: 24814141
DOI: 10.1016/j.psychres.2014.04.030

Abstract

We investigated the association between remission of depressive symptoms in fluvoxamine treatment and catechol-O-methyltransferase (COMT) gene. Sixteen SNPs in the COMT gene were investigated in 123 outpatients with major depression. Three single nucleotide polymorphisms located in the 5' region were associated with remission in fluvoxamine-treated outpatients with moderate to severe depression.

Keywords: COMT; Depression; Fluvoxamine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antidepressive Agents, Second-Generation / administration & dosage*
Catechol O-Methyltransferase / genetics*
Depressive Disorder, Major / drug therapy*
Depressive Disorder, Major / enzymology*
Female
Fluvoxamine / administration & dosage*
Humans
Male
Middle Aged
Promoter Regions, Genetic*
Treatment Outcome

Substances

Antidepressive Agents, Second-Generation
Catechol O-Methyltransferase
Fluvoxamine